Akriti Jain, MD, discusses what she is most looking forward to seeing presented at the upcoming 2024 American Society of Hematology Annual Meeting and Exposition. #ASH24 #ASH2024 @clevelandclinic.bsky.social www.targetedonc.com/view/excitin...

Who knew we would have 5 options for frontline CML management! Read our review to find out how to choose!

Amazing talk using analogies from football on Tackling Anemia in MF by @aarongerds.bsky.social #mpncongress #mpnsm

JAK Inhibitor Selection and Sequencing Strategies Are Key in #Myelofibrosis Management @akritigjain.bsky.social #oncology www.onclive.com/view/jak-inh...

It's time for the #FiveUnder5 🕓, your go-to roundup of the top 5 #oncology videos of the week. @washumedicine.bsky.social @akritigjain.bsky.social @clevelandclinic.bsky.social @cityofhope.bsky.social @harvardmed.bsky.social Watch the clips: 📽️: www.onclive.com/view/five-un... #bcsm #mmsm

THIRD! Dr. Andrew Kuykendall presents VERIFY: rusfertide vs placebo for polycythemia vera. During weeks 20-32, more patients who received rusfertide achieved a clinical response, 76.9 vs 32.9%, p<0.0001. Patients received fewer phlebotomies and had less fatigue. #ASCO25

Listen to our Cancer Advances Podcast on personalizing treatment of myelofibrosis related anemia! @clevelandclinic.bsky.social my.clevelandclinic.org/podcasts/can...

My first @bloodjournal.bsky.social article!

Let’s Go Buffalo! @buffalo-bills.bsky.social